FOX04-DRI 10 MG

FOX04-DRI 10 mg – Peptide Hubs

FOX04-DRI is a cutting-edge synthetic peptide designed to selectively induce apoptosis in senescent cells while preserving healthy tissue. By interfering with the FOXO4-p53 interaction, this peptide holds immense potential in research related to cellular aging, tissue regeneration, and age-related pathologies. Peptide Hubs offers a 10 mg lyophilized vial of FOX04-DRI, designed for stable and precise use in experimental setups.

What Is FOX04-DRI?

FOX04-DRI (FOXO4 D-Retro-Inverso) is a modified peptide sequence that mimics a portion of the natural FOXO4 protein but with reverse amino acid direction and D-amino acids for enhanced stability. It works by disrupting the binding of FOXO4 to p53, allowing senescent cells to undergo apoptosis without harming healthy cells. Its primary relevance lies in the field of senolytics—therapies aimed at removing aging or "zombie" cells. For more on the underlying science, read this NIH study on FOXO4-DRI and senescence clearance.

Research Applications

FOX04-DRI is being evaluated in a growing number of research fields, including:

• Cellular senescence and anti-aging interventions
• Tissue regeneration and wound healing models
• Neurodegenerative disease research
• Targeted cancer therapy resistance pathways

Because of its ability to clear senescent cells selectively, it has been studied alongside GHK-CU for skin and tissue rejuvenation, or BPC-157 to support musculoskeletal repair where senescence hinders recovery.

Suggested Experimental Use

• Dosage: 5–10 mg per week in cycles of 2–4 weeks
• Administration: Subcutaneous or intraperitoneal (based on research model)
• Cycle Frequency: Intermittent cycling recommended to avoid systemic senescent depletion

Peptide Stacking Options

Researchers may pair FOX04-DRI with synergistic peptides to study comprehensive regeneration and immune modulation:

• AOD 9604 – for lipolytic activity during tissue repair
• DSIP – to monitor recovery sleep and HPA axis balance post-clearing
• Cartalax – for cartilage/tendon regeneration in degenerative conditions
• Chonluten – for immune resilience during age-related lung degeneration

Safety and Legality

FOX04-DRI is for **research use only**. It is not approved by the FDA for human use and should not be administered to humans or animals outside controlled laboratory environments. While early animal models suggest selective cytotoxicity toward senescent cells, researchers should implement rigorous safety and monitoring protocols when working with senolytic peptides.

To monitor regulatory updates or peer-reviewed developments on FOX04-DRI, refer to ClinicalTrials.gov.

Frequently Asked Questions